You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing an automated yeast dissection system for aging research
SBC: Innovative BioChips LLC Topic: NIAPROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
CCN3-derrived peptides to treat liver injury
SBC: BLR Bio Topic: 200Project Summary Chronic liver disease is becoming a major public health issue with estimates of up to 40% prevalence of non- alcoholic fatty liver disease (NAFLD) and 12% with non-alcoholic steatohepatitis (NASH) in the U.S. Liver disease and cirrhosis was the 12th leading cause of mortality in the U.S. in 2014. Obesity and metabolic syndrome are important causes of fatty liver disease or steatosi ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
SBC: REVERAGEN BIOPHARMA, INC. Topic: NICHDThere is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Expansion of Immuno-CometChip Platform
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHSProject SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)
SBC: NANOHYBRIDS INC Topic: NABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIAIn the USthe number of individuals agedand older will increase byover the next decadeConcurrentlyMedicare costs are expected to double to treat chronic diseases that will plague this increasing number of older adultsOne of the most wide spread chronic diseases that affects older adults is sarcopeniawhich is observed inof adults overyears of age andof adults overyears of ageThis disease is characte ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health